Organization (Industry)
Talaris Therapeutics (United States)
ClinicalTrials.gov lists Talaris Therapeutics (United States) as lead sponsor of 12 trials. It has 28 active development programs.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Talaris Therapeutics (United States): 12 lead-sponsored trials and 1 legal-entity registration.
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Leukodystrophy, Metachromatic | 3 |
| Anemia | 2 |
| Anemia, Aplastic | 2 |
| Anemia, Sickle Cell | 2 |
| Adrenal Insufficiency | 1 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2019 | 1 |
| 2012 | 1 |
| 2011 | 2 |
| 2008 | 1 |
| 2007 | 1 |
| 2005 | 2 |
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (28)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Enriched Hematopoetic Stem Cell Infusion | Anemia, Sickle Cell | Phase 1/2 | 2 |
| Enriched Hematopoetic Stem Cell Infusion | Anemia, Aplastic | Phase 1/2 | 2 |
| Enriched Hematopoetic Stem Cell Infusion | Anemia | Phase 1/2 | 2 |
| Hematopoietic stem cell infusion | Adrenal Insufficiency | Phase 1/2 | 1 |
| Hematopoietic stem cell infusion | Death | Phase 1/2 | 1 |
Showing 5 of 28 active programs.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0% hit target (n=6) | 100% on time (n=5) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Transplantation | 2 |
| Frontiers in immunology | 1 |
| Journal of the American Society of Nephrology : JASN | 1 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2020-09-22 | Private placement | 114,999,989 | Form d |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| St. Christopher's Hospital for Children | Co sponsors trial with | 1 |
| Medical College of Pennsylvania Hospital | Co sponsors trial with | 1 |
| The Western Pennsylvania Hospital | Co sponsors trial with | 1 |
Latest dated events (10)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2021-11-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-09-22 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2019-10-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2012-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2011-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 10 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| TALARIS THERAPEUTICS | Certificate of compliance | Terminated |
Biomarker capability evidence (36)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD1 | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| AMN | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 36 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and biomarkers this organization publishes on.